News

TCD screening underused in sickle cell patients


 

Doctor examines patient

with sickle cell anemia

Photo courtesy of St. Jude

Results of a large, retrospective study suggest the use of transcranial Doppler (TCD) screening is on the rise in US children and adolescents with sickle cell anemia.

However, the rate of TCD screening in these patients falls well below national recommendations.

In addition, TCD screening rates vary greatly by state, and the use of screening tends to decrease as patients grow older.

Sarah L. Reeves, PhD, of University of Michigan, Ann Arbor, and her colleagues reported these findings in JAMA Pediatrics.

The researchers noted that guidelines from the National Heart, Lung, and Blood Institute recommend that patients with sickle cell anemia receive annual TCD screenings from age 2 to 16 to identify those patients at the highest risk of stroke.

Dr Reeves and her colleagues wanted to determine if this recommendation is being followed. So they analyzed Medicaid claims data from 2005 through 2010 for Florida, Illinois, Louisiana, Michigan, South Carolina, and Texas.

The data included 4775 patients, ages 2 to 16, with sickle cell anemia. For these patients, TCD screening rates increased from 22% in 2005 to 44% in 2010 (P<0.001).

The researchers found that TCD screening rates varied significantly by state (P=0.004), and Texas had the lowest screening rate at any time point (7% in 2005).

The team also analyzed a subset of 2388 patients who were enrolled for 2 or more consecutive years to examine potential predictors of TCD screening.

This analysis revealed that, with each year of increasing age, a patient’s odds of receiving TCD screening decreased (odds ratio=0.97, P=0.002).

On the other hand, an increasing number of well-child visits was associated with higher odds of receiving TCD screening (odds ratio=1.10, P=0.007).

And the odds of receiving TCD screening were higher for patients who previously underwent TCD screening (odds ratio=2.44, P<0.001).

The researchers said these results suggest that, despite national recommendations, TCD screening rates remain low in young patients with sickle cell anemia in the US.

Recommended Reading

Colombia reports first Zika deaths, all in medically compromised patients
MDedge Hematology and Oncology
Sickle cell anemia: Stroke screening still underused
MDedge Hematology and Oncology
Slowing the progression of sickle cell disease
MDedge Hematology and Oncology
EC approves drug for pediatric ITP
MDedge Hematology and Oncology
Drug bests placebo in iron deficiency anemia trial
MDedge Hematology and Oncology
Drug exhibits preclinical activity against MDS
MDedge Hematology and Oncology
mAb gets breakthrough designation for HLH
MDedge Hematology and Oncology
Drug may best BSC in some high-risk MDS patients
MDedge Hematology and Oncology
Germline mutations linked to hematologic malignancies
MDedge Hematology and Oncology
System could aid assessment of sickle cell disease
MDedge Hematology and Oncology